Investigational drug · Phase 3
Gen 2 Travoprost Intracameral Implant
Also called: Gen 2 Travoprost Intraocular Implant
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glaucoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Gen 2 Travoprost Intracameral Implant"
First trial start
2025
Jun 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Gen 2 Travoprost Intracameral Implant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glaucoma
Approved drugs for the same conditions: Glaucoma · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Gen 2 Travoprost Intracameral Implant" as an intervention, largest first.
- Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantPivotal-lookingRecruiting
Glaukos CorporationIndustry
NCT07495852 · 510 participants (planned) · Start Feb 17, 2026 · Primary completion Jun 2028
Drug: Gen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5% · For: Glaucoma
Sites: Dothan, Alabama
- Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantPivotal-lookingRecruiting
Glaukos CorporationIndustry
NCT07075718 · 110 participants (planned) · Start Jun 12, 2025 · Primary completion Mar 2028
Drug: Gen 2 Travoprost Intracameral Implant; Timolol eye drops 0.5% · For: Glaucoma
Sites: Grand Junction, Colorado; Oklahoma City, Oklahoma; El Paso, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Glaucoma
- Bimatoprost Implant SystemPhase 33 trials
SpyGlass Pharma, Inc. · Cataract, Glaucoma, Ocular Hypertension
- Timolol eye drops 0.5%Phase 33 trials
Glaukos Corporation · Glaucoma, Ocular Hypertension
- Inactive controlQLS-111 vehiclePhase 32 trials
Can-Fite BioPharma · Hepatocellular Carcinoma, Cirrhosis, Open-angle Glaucoma (OAG)
- QLS-111Phase 23 trials
Qlaris Bio, Inc. · Normal Tension Glaucoma (NTG), Glaucoma, Open-angle Glaucoma (OAG)
- BL1107Phase 22 trials
Bausch & Lomb Incorporated · Dry Eye Disease, Glaucoma
- ASP2767Phase 21 trial
Astellas · Glaucoma
- intraocular implant releasing timololTimoD implantPhase 21 trial
EyeD Pharma · Glaucoma, Ocular Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.